Medicalgorithmics S.A.

East Value Research

Price target: PLN 48.60 | Update | Rating: BUY

Medicalgorithmics' (MDG) Q3 and 9M/25 results came in above our expectations. They reflected the impact of 19 new clients acquired so far in 2025, including the fifth-largest Independent Diagnostic Testing Facility (IDTF) in the US, whose contribution to MDG's revenues has accelerated in recent months and already exceeded the contractual minimum monthly revenue of USD 60.8k in September. With 284,933 ECG reports (sessions) in 9M/25 — which form the basis for revenues in the company's Services segment — the volume has already surpassed the total for all of 2024. As monthly revenues from the large US-based IDTF are expected to rise further to USD 300k (PLN 1.09m) in November/December according to management, and given that the number of sessions in 9M/25 exceeded our expectations, we have raised our 2025E revenue forecast by 3.4%. In early November, the company also signed a new contract for the use of its DeepRhythm Platform (DRP) with one of the largest IDTFs in the UK & Ireland, which we estimate generates >100,000 ECG reports per year. Reflecting the higher 2025E estimates, revised CAPEX assumptions (PLN 42.7m for 2025E–2028E vs. PLN 37.7m previously), and a lower WACC of 11.7% (prev. 12.5%), we derive a new 12-months DCF-based PT of PLN 48.60 (prev. PLN 43.80). Given the current upside of 45.1%, we maintain our BUY rating for the stock.

In 9M/25, Medicalgorithmics' revenues increased by 15.4% y-o-y to PLN 20.9m, while in Q3/25 they rose by 38% to PLN 7.2m. Sales in the Services segment (reflecting platform and algorithm-based revenues) grew by 26.7% to PLN 19.7m, while revenues from Products (= device sales) declined less than we had expected, by 51.2% to PLN 1.3m. Driven by the large US client, sales from that market grew the fastest, up 74.2% y-o-y to PLN 6.7m. For Jan-Sep 2025, Medicalgorithmics reported an EBIT and net income of PLN -9.4m (9M/24: PLN -11.4m) and PLN -10.8m (PLN -11.5m) respectively. As expected, the company recorded a higher net loss q-o-q in Q3/25 mainly due to integration costs of its solutions. Positively, operating cash flow improved significantly to PLN -3.6m (from PLN -11.6m in 9M/24). However, CAPEX of PLN 9.6m (9M/24: PLN 4.2m) was higher than we had anticipated. Net debt increased q-o-q to PLN 16.8m (from PLN 12.8m after H1/25), following additional debt financing from Biofund. Management maintains its guidance that Medicalgorithmics will reach operating break-even by the end of Q4/25/beginning of Q1/26. Regarding the VCAST platform for 3D analysis of coronary arteries, MDG has begun integration with three initial clients in Sweden, Saudi Arabia, and Turkey.

in PLNm	2023	2024	2025E	2026E	2027E	2028E
Net sales	43.10	24.00	30.02	58.27	89.91	116.47
EBITDA	2.80	-12.90	-6.03	7.83	16.38	26.24
EBIT	0.43	-16.54	-10.43	2.99	11.06	20.38
Net income	-0.58	-16.08	-11.64	0.40	7.01	14.65
EPS	-0.06	-1.62	-1.17	0.04	0.70	1.47
DPS	0.00	0.00	0.00	0.00	0.00	0.00
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
RoE	-0.62%	-20.84%	-17.77%	0.60%	9.62%	16.72%
Net gearing	-21.41%	0.97%	34.53%	43.40%	38.10%	22.84%
EV/Sales	8.13x	14.59x	11.66x	6.01x	3.90x	3.01x
EV/EBITDA	125.17x	neg	neg	44.73x	21.38x	13.35x
P/E	neg	neg	neg	841.37x	47.54x	22.76x

Company profile

Medicalgorithmics S.A. is a Polish provider of AI-based software for the analysis of the heart with clients in >25 countries in Europe, North America, Asia and Australia. Medicalgorithmics employs >150 people.

Date of publication	13 November 2025 / 8:15 am
Website	www.medicalgorithmics.com
Sector	Healthcare Software
Country	Poland
ISIN	PLMDCLG00015
Reuters	MDG.WA
Bloomberg	MDG PW

Share information

Last price	33.50
Number of shares (m)	9.95
Market cap. (PLNm)	333.42
Market cap. (EURm)	78.82
52-weeks range	PLN 42.80 / PLN 15.57
Average volume (shares)	47,420

Performance

4-weeks	-0.30%
13-weeks	-3.87%
26-weeks	31.83%
52-weeks	53.90%
YTD	98.52%

Shareholder structure

Biofund Capital Management	34.92%
Free float	65.08%

Financial calendar

Annual Report 2025 (exp.)	April 30, 2026

Analyst

Adrian Kowollik
a.kowollik@eastvalueresearch.com

Current trading & our forecasts

In 9M/25, Medicalgorithmics' revenue growth accelerated. Revenues increased by 15.4% y-o-y to PLN 20.9m, compared to a 6.3% y-o-y increase after H1/25. This improvement was driven by a 26.7% rise in revenues in the Services segment, reflecting sales of the proprietary DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) algorithms. In Q3/25, the number of sessions grew by 33.5% y-o-y to 96,627 but remained flat q-o-q due to seasonality (during the holiday period, the number of ECG exams — equivalent to reports or sessions — tends to be relatively low). Strong growth in the Services segment contributed to an increase in the gross margin from 16.0% in 9M/24 to 20.7% (H1/25: 26.4%). The largest component of MDG's cost of goods sold (CoGS) were external services (+16.2% y-o-y to PLN 13.5m), mainly reflecting cloud service costs that rise in line with the revenue growth of the Services segment.



Source: Company information, East Value Research GmbH

Between January and September 2025, clients from the US continued to be the main growth driver and their share in total revenues went up to 32% from 21.2% last year (Poland: 13.9% vs. 16%). The number of new signed contracts with partners from the US, Canada, Turkey and Europe reached 19 (thereof 3 from the US).

What surprised us in the 9M/25 report were higher-than-expected depreciation and a lower-than-expected tax result. Our model adjustments — namely a 10% higher estimate for depreciation and amortisation expenses and a PLN 2.5m lower tax refund in 2025E compared to previous assumptions — affect only our EBIT and EBITDA forecasts for 2025E and the EBITDA estimates for 2026E–2028E. Given the higher-than-expected number of sessions in 9M/25 and the accelerating sales from the large US-based IDTF in Q4/25 — which will likely increase q-o-q growth in the number of ECG reports/sessions — we have raised our estimate for the number of sessions in full-year 2025E from 345,000 to 383,000 (while MDG's management guides for 500,000), however at a lower average price per ECG report of PLN 75 (prev. PLN 80).

Below are our detailed estimates for Medicalgorithmics' revenues and profitability in 2025E-2028E. We would like to emphasize that our current revenue forecasts do not account for the VCAST platform, which could generate first revenues in H2/26E at an up to 10x higher average price per session than the company's DRP software. Medicalgorithmics' VCAST platform uses proprietary artificial intelligence algorithms to convert cardiac CT scan data - according to MDG's management "every hospital owns a CT" due to its relatively low costs compared to e.g. MRI - into 3D models of coronary arteries and analyses them to identify vessels with narrowing caused by atherosclerotic plaque.

in PLNm	2025E	2026E	2027E	2028E
Services	**28.73**	**57.10**	**88.86**	**115.52**
(% of net sales)	*95.7%*	*98.0%*	*98.8%*	*99.2%*
Number of reports	383,000	761,333	1,184,800	1,540,267
Average price per report (PLN)	75	75	75	75
Products (PocketECG, Kardiobeat.ai)	**1.30**	**1.17**	**1.05**	**0.95**
(% of net sales)	*4.3%*	*2.0%*	*1.2%*	*0.8%*
Number of devices	720	648	583	525
Average price per device (PLN)	1,805	1,805	1,805	1,805
Total net sales	**30.02**	**58.27**	**89.91**	**116.47**
(change y-o-y)	25.1%	94.1%	54.3%	29.5%

Source: East Value Research GmbH

	2025E		2026E		2027E		2028E	
in PLNm	new	old	new	old	new	old	new	old
Net sales	**30.02**	**29.04**	**58.27**	**58.27**	**89.91**	**89.91**	**116.47**	**116.47**
EBITDA	**-6.03**	**-9.07**	**7.83**	**7.39**	**16.38**	**15.90**	**26.24**	**25.71**
EBITDA margin	*-20.1%*	*-31.2%*	*13.4%*	*12.7%*	*18.2%*	*17.7%*	*22.5%*	*22.1%*
EBIT	**-10.43**	**-13.07**	**2.99**	**2.99**	**11.06**	**11.06**	**20.38**	**20.38**
EBIT margin	*-34.8%*	*-45.0%*	*5.1%*	*5.1%*	*12.3%*	*12.3%*	*17.5%*	*17.5%*
Net income	**-11.64**	**-11.64**	**0.40**	**0.40**	**7.01**	**7.01**	**14.65**	**14.65**
Net margin	*-38.8%*	*-40.1%*	*0.7%*	*0.7%*	*7.8%*	*7.8%*	*12.6%*	*12.6%*

Source: East Value Research GmbH

Valuation

After accounting for higher estimates for 2025E, a lower WACC (11.7% vs. 12.5% before) and higher assumptions for CAPEX in 2025E-2028E, which reflect the company's investments in the development of its software and algorithms, we arrive at a new 12-months DCF-based PT of PLN 48.60 (prev. PLN 43.80), which implies a BUY rating at present. We do not account for the peer group in our valuation as in our view there are no appropriate listed peers with sell-side estimates.

Below are the key assumptions of our WACC calculation:

(1) *Risk-free rate*: Current yield of Polish long-term government bonds with maturity in 2047E is 5.5% (Source: www.boerse-stuttgart.de)

(2) *Beta*: 4y average unlevered beta of companies from the Healthcare Information and Technology sector of 1.14x (Source: www.damodaran.com)

(3) *Levered beta*: 1.54x

(4) *Equity risk premium (Poland)*: 5.46% (Source: www.damodaran.com)

(5) *Effective tax rate*: 19%

(6) *After-tax debt costs*: 6.5%

(7) *Equity costs*: 13.9%

(8) WACC: 11.7%

(9) Free cash flows are discounted to November 12, 2025.

DCF model

in PLNm	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E
Net sales	**30.02**	**58.27**	**89.91**	**116.47**	**151.03**	**180.98**	**216.04**	**249.34**	**286.61**
(y-o-y change)	25.1%	94.1%	54.3%	29.5%	29.7%	19.8%	19.4%	15.4%	14.9%
EBIT	**-10.43**	**2.99**	**11.06**	**20.38**	**33.23**	**50.67**	**75.61**	**87.02**	**98.38**
(EBIT margin)	-34.8%	5.1%	12.3%	17.5%	22.0%	28.0%	35.0%	34.9%	34.3%
NOPLAT	**-10.27**	**2.42**	**8.96**	**16.51**	**26.91**	**41.05**	**61.25**	**70.49**	**79.69**
+ Depreciation & amortisation	4.40	4.84	5.32	5.86	6.44	7.09	7.79	8.57	9.43
= Net operating cash flow	-5.87	7.26	14.28	22.37	33.36	48.13	69.04	79.06	89.12
- Total investments (Capex and WC)	-10.29	-11.61	-10.68	-10.46	-11.88	-12.84	-14.71	-14.29	-15.68
Capital expenditure	-13.11	-9.35	-9.83	-10.37	-7.86	-8.51	-9.21	-9.99	-10.85
Working capital	2.82	-2.26	-0.85	-0.10	-4.02	-4.33	-5.50	-4.30	-4.83
= Free cash flow (FCF)	-16.16	-4.34	3.60	11.90	21.47	35.29	54.33	64.77	73.44
PV of FCF's	**-15.92**	**-3.83**	**2.85**	**8.42**	**13.61**	**20.03**	**27.61**	**29.48**	**29.94**

PV of FCFs in explicit period	112.19
PV of FCFs in terminal period	337.80
Enterprise value (EV)	**449.99**
+ Net cash / - net debt (30 September 2025)	-16.80
+ Investment / - minorities	-0.02
Shareholder value	**433.17**
Number of shares outstanding (m)	**9.95**
WACC	**11.7%**
Cost of equity	13.9%
Pre-tax cost of debt	8.0%
Normal tax rate	19.0%
After-tax cost of debt	6.5%
Share of equity	70.0%
Share of debt	30.0%
Fair value per share in PLN (today)	**43.52**
Fair value per share in PLN (in 12 months)	**48.60**

		Terminal EBIT margin						
		31.3%	**32.3%**	**33.3%**	**34.3%**	**35.3%**	**36.3%**	**37.3%**
WACC	**7.7%**	93.73	96.30	98.88	101.45	104.02	106.59	109.17
	8.7%	75.91	77.94	79.97	82.00	84.03	86.05	88.08
	9.7%	62.89	64.53	66.16	67.80	69.44	71.07	72.71
	10.7%	52.99	54.33	55.68	57.02	58.37	59.71	61.06
	11.7%	45.24	46.36	47.48	**48.60**	49.72	50.84	51.96
	12.7%	39.02	39.97	40.91	41.86	42.80	43.75	44.69
	13.7%	33.95	34.75	35.56	36.36	37.16	37.97	38.77

Source: East Value Research GmbH

Peer Group Analysis

Most of Medicalgorithmics' listed competitors are large and diversified global MedTech companies. We have identified the following peers:

(1) *iRhythm Technologies Inc.*: iRhythm, which is based in San Francisco/US, provides advanced ambulatory cardiac monitoring solutions using wearable biosensor devices, supported by data analytics and machine learning for arrhythmia diagnosis. iRhythm's primary product is the Zio service, which includes Zio XT and Zio AT wearable cardiac patches that monitor heart rhythms continuously for up to 14 days. The patches are prescribed by physicians, worn by patients, then returned for data analysis. iRhythm processes this data with proprietary algorithms and provides actionable diagnostic reports to clinicians. In 2024, iRhythm generated revenues of USD 591.8m and an EBITDA of USD -65.6m. Its market cap equals USD 5.7bn.

(2) *Biotricity Inc.*: Biotricity, which is based in Redwood City/USA, offers a combination of wearable cardiac monitoring devices and a cloud-based AI-driven analytics platform called the Cardiac AI Cloud, which processes large volumes of cardiac data to provide advanced diagnostic insights to clinicians. The company generates recurring revenue through technology service fees that are significantly larger than device sales revenues. In fiscal-year 2024/25, Biotricity, which has a market cap of USD 14.8m, generated revenues of USD 13.8m and an EBITDA of USD -2.4m.

(3) *HeartFlow Inc.*: HeartFlow, which is based in Mountain View/US, provides a software-as-a-service (SaaS) platform that utilizes artificial intelligence and computational fluid dynamics to create personalized 3D models of patients' coronary arteries from coronary computed tomography angiography (CTA) scans. The company offers its flagship product, the HeartFlow Analysis, which non-invasively diagnoses and helps manage coronary artery disease by providing detailed insights on blood flow, stenosis, and plaque composition. In 2024, HeartFlow, whose current market cap equals USD 2.9bn, generated revenues of USD 125.8m and an EBITDA of USD -59.6m.

(4) *Koninklijke Philips NV*: Philips, which is based in Amsterdam/The Netherlands, provides large-scale medical equipment such as MRI, X-ray, patient monitoring devices, and homecare products, along with innovative digital health solutions including AI-based analytics and remote monitoring services. The company is shifting towards circular business models like product-as-a-service (PaaS), where customers lease equipment, allowing Philips to maintain control and optimize lifecycle management through refurbishment, upgrades, and take-back programs. In 2024, Philips, which has a market cap of EUR 23.8bn, generated revenues of EUR 18bn and an EBITDA margin of 8.8%. Its ROCE equalled 3.3%.

(5) *Siemens Healthineers AG:* Siemens Healthineers, which is based in Forchheim/Germany, offers advanced medical imaging systems, diagnostic solutions, and advanced therapies, combining hardware with digital services, AI-driven data analytics, and automation to enhance clinical decision-making and operational efficiency. In fiscal-year 2024/25, the company, which has a market cap of EUR 49.4bn, generated revenues of EUR 23.4bn and an EBITDA margin of 19.1%. Its ROCE equalled 7%.

(6) *GE Healthcare Inc.*: GE Healthcare, which is headquartered in Chicago/US, operates four main segments: Medical Imaging (MRI, CT, X-ray, ultrasound), Advanced Visualization Solutions (AI and software for image analysis), Patient Care Solutions (monitoring, anesthesia, respiratory care), and Pharmaceutical Diagnostics (contrast agents and radiopharmaceuticals). In 2024, the company, which has a market cap of EUR 33.4bn, generated revenues of USD 19.7bn and an EBITDA margin of 18.3%. Its ROCE equalled 10.2%.

(7) *Abbott Laboratories Inc.*: Abbott, which is headquartered in North Chicago/US, operates through four main segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals, with a strong focus on innovation-driven growth and global market expansion. Its Medical Devices segment drives growth through products like the FreeStyle Libre continuous glucose monitoring system for diabetes care and cardiovascular innovations such as leadless pacemakers and structural heart solutions. In 2024, Abbott Laboratories, which has a market cap of USD 220.8bn, generated revenues of USD 42bn and an EBITDA margin of 25.5%. Its ROCE equalled 8.8%.

	EV/Sales		EV/EBITDA		P/E		P/BVPS	EBITDA margin	Net gearing
Company	**2025E**	**2026E**	**2025E**	**2026E**	**2025E**	**2026E**	**Latest**	**Last FY**	**Latest**
iRhytm Technologies Inc.(USD)	7.92x	6.78x	95.48x	57.97x	n.a	n.a	46.57x	neg	137.65%
Biotricity Inc. (USD)	2.74x	n.a	n.a	n.a	n.a	n.a	neg	neg	n.a
HeartFlow Inc. (USD)	22.61x	18.10x	n.a	n.a	n.a	n.a	neg	neg	n.a
Koninklijke Philips NV (EUR)	1.70x	1.65x	10.02x	9.66x	17.15x	15.95x	2.26x	8.85%	61.34%
Siemens Healthineers AG (EUR)	2.57x	2.41x	12.56x	11.21x	18.59x	16.10x	2.74x	19.08%	69.99%
GE Healthcare Inc. (USD)	1.97x	1.89x	11.17x	10.40x	16.13x	14.86x	3.35x	18.33%	67.44%
Abbott Laboratories Inc. (USD)	5.07x	4.71x	19.17x	17.44x	24.66x	22.36x	4.33x	25.54%	10.29%
Median	**2.74x**	**3.56x**	**12.56x**	**11.21x**	**17.87x**	**16.02x**	**3.35x**	**18.71%**	**67.44%**
Medicalgorithmics S.A. (PLN)	11.66x	6.01x	n.a	44.73x	n.a	841.37x	5.06x	-53.76%	25.50%
Premium/Discount	***326.1%***	***68.9%***	***n.a***	***299.0%***	***n.a***	***5150.9%***			

Source: CapitalIQ, East Value Research GmbH

Profit and loss statement

in PLNm	2023	2024	2025E	2026E	2027E	2028E
Net sales	**43.10**	**24.00**	**30.02**	**58.27**	**89.91**	**116.47**
Cost of goods sold	-21.71	-20.27	-22.52	-33.80	-55.75	-71.05
Gross profit	**21.39**	**3.73**	**7.51**	**24.47**	**34.17**	**45.42**
Other operating income	0.87	4.82	2.05	2.07	2.09	2.11
Personnel costs	-18.06	-18.22	-14.11	-17.42	-18.72	-20.13
Other operating expenses	-1.41	-3.23	-1.48	-1.30	-1.15	-1.17
EBITDA	**2.80**	**-12.90**	**-6.03**	**7.83**	**16.38**	**26.24**
Depreciation & Amortization	-2.37	-3.64	-4.40	-4.84	-5.32	-5.86
EBIT	**0.43**	**-16.54**	**-10.43**	**2.99**	**11.06**	**20.38**
Net financial results	-0.67	0.76	-1.40	-2.50	-2.40	-2.30
EBT	**-0.24**	**-15.78**	**-11.83**	**0.49**	**8.66**	**18.08**
Income taxes	-0.34	-0.30	0.19	-0.09	-1.65	-3.44
Result from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
Minority interests	0.00	0.00	0.00	0.00	0.00	0.00
Net income / loss	**-0.58**	**-16.08**	**-11.64**	**0.40**	**7.01**	**14.65**
EPS	-0.06	-1.62	-1.17	0.04	0.70	1.47
DPS	0.00	0.00	0.00	0.00	0.00	0.00
Share in total sales						
Net sales	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %
Cost of goods sold	-50.36 %	-84.45 %	-75.00 %	-58.00 %	-62.00 %	-61.00 %
Gross profit	49.64 %	15.55 %	25.00 %	42.00 %	38.00 %	39.00 %
Other operating income	2.02 %	20.08 %	6.83 %	3.55 %	2.33 %	1.81 %
Personnel costs	-41.89 %	-75.92 %	-47.00 %	-29.89 %	-20.82 %	-17.28 %
Other operating expenses	-3.27 %	-13.47 %	-4.92 %	-2.23 %	-1.28 %	-1.00 %
EBITDA	6.49 %	-53.76 %	-20.10 %	13.44 %	18.22 %	22.53 %
Depreciation & Amortization	-5.49 %	-15.14 %	-14.65 %	-8.31 %	-5.92 %	-5.03 %
EBIT	1.00 %	-68.90 %	-34.75 %	5.13 %	12.30 %	17.50 %
Net financial results	-1.56 %	3.17 %	-4.66 %	-4.29 %	-2.67 %	-1.97 %
EBT	-0.55 %	-65.73 %	-39.41 %	0.84 %	9.63 %	15.53 %
Income taxes	-0.79 %	-1.26 %	0.63 %	-0.16 %	-1.83 %	-2.95 %
Result from discontinued operations	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %	0.00 %
Minority interests	0.00 %	-0.01 %	0.00 %	0.00 %	0.00 %	0.00 %
Net income / loss	-1.34 %	-67.00 %	-38.78 %	0.68 %	7.80 %	12.58 %

Balance sheet

in PLNm	2023	2024	2025E	2026E	2027E	2028E
Cash and cash equivalents	25.50	5.50	1.11	1.93	0.55	3.13
Other financial assets	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	9.32	9.39	6.17	5.00	2.90	0.00
Trade accounts and notes receivables	4.22	4.28	4.86	9.44	14.59	18.93
Prepaid expenses, deferred charges and others	4.19	3.20	3.26	3.32	3.39	3.46
Current assets	**43.23**	**22.37**	**15.40**	**19.69**	**21.43**	**25.52**
Property, plant and equipment	2.28	2.35	3.06	3.07	3.08	3.09
Other intangible assets	54.50	60.27	68.27	72.77	77.27	81.77
Goodwill	18.21	18.21	18.21	18.21	18.21	18.21
Other long-term assets	3.42	2.62	2.49	2.37	2.25	2.14
Deferred tax assets	0.00	0.00	0.00	0.00	0.00	0.00
Non-current assets	**78.40**	**83.45**	**92.02**	**96.41**	**100.80**	**105.20**
Total assets	**121.63**	**105.81**	**107.42**	**116.10**	**122.23**	**130.72**
Trade payables	3.14	2.42	2.59	3.75	5.96	7.30
Short-term financial debt	3.22	0.77	0.74	0.54	0.34	0.14
Other liabilities	3.35	3.13	3.16	3.19	3.23	3.26
Pension provision	2.59	2.65	3.70	4.07	4.48	4.92
Current liabilities	**12.29**	**8.97**	**10.19**	**11.56**	**14.00**	**15.62**
Long-term financial debt	2.47	5.48	23.00	30.00	28.00	23.00
Other long-term liabilities	5.59	5.16	0.00	0.00	0.00	0.00
Pension provision	0.15	0.09	0.09	0.09	0.09	0.10
Deferred tax liabilities	8.57	8.93	8.59	8.52	7.19	4.40
Long-term liabilities	**16.77**	**19.66**	**31.69**	**38.61**	**35.28**	**27.50**
Total liabilities	**29.07**	**28.63**	**41.88**	**50.17**	**49.28**	**43.12**
Shareholders equity	**92.56**	**77.17**	**65.53**	**65.93**	**72.94**	**87.59**
Minority interests	0.01	0.01	0.01	0.01	0.01	0.01
Total liabilities and equity	**121.63**	**105.81**	**107.42**	**116.10**	**122.23**	**130.72**

Cash Flow Statement

in PLNm	2023	2024	2025E	2026E	2027E	2028E
Net income / loss	-0.58	-16.08	-11.64	0.40	7.01	14.65
Depreciation & Amortization	2.37	3.64	4.40	4.84	5.32	5.86
Change of working capital	-5.46	-0.36	2.82	-2.26	-0.85	-0.10
Others	3.86	-0.28	4.35	-0.39	0.84	2.26
Net operating cash flow	**0.18**	**-13.08**	**-0.08**	**2.59**	**12.33**	**22.66**
Cash flow from investing	**1.96**	**-7.37**	**-13.11**	**-9.35**	**-9.83**	**-10.37**
Free cash flow	2.15	-20.44	-13.19	-6.76	2.50	12.30
Cash flow from financing	**-2.81**	**0.45**	**8.80**	**7.57**	**-3.88**	**-9.71**
Change of cash	-0.66	-20.00	-4.39	0.82	-1.38	2.58
Cash at the beginning of the period	0.00	25.50	5.50	1.11	1.93	0.55
Cash at the end of the period	25.50	5.50	1.11	1.93	0.55	3.13

Financial ratios

Fiscal year	2023	2024	2025E	2026E	2027E	2028E
Profitability and balance sheet quality						
Gross margin	49.64%	15.55%	25.00%	42.00%	38.00%	39.00%
EBITDA margin	6.49%	-53.76%	-20.10%	13.44%	18.22%	22.53%
EBIT margin	1.00%	-68.90%	-34.75%	5.13%	12.30%	17.50%
Net margin	-1.34%	-67.00%	-38.78%	0.68%	7.80%	12.58%
Return on equity (ROE)	-0.62%	-20.84%	-17.77%	0.60%	9.62%	16.72%
Return on assets (ROA)	0.08%	-15.92%	-9.54%	2.49%	7.70%	12.96%
Return on capital employed (ROCE)	0.96%	-17.40%	-10.56%	2.32%	8.28%	14.34%
Economic Value Added (in PLNm)	-11.70	-28.15	-21.61	-9.77	-3.67	3.08
Net debt (in PLNm)	-19.81	0.75	22.63	28.61	27.79	20.01
Net gearing	-21.41%	0.97%	34.53%	43.40%	38.10%	22.84%
Equity ratio	76.10%	72.93%	61.00%	56.78%	59.67%	67.00%
Current ratio	3.52	2.49	1.51	1.70	1.53	1.63
Quick ratio	2.42	1.09	0.59	0.98	1.08	1.41
Net interest cover	0.65	21.73	-7.45	1.20	4.61	8.86
Net debt/EBITDA	-7.08	-0.06	-3.75	3.65	1.70	0.76
Tangible BVPS	7.72	5.94	4.75	4.79	5.50	6.97
Capex/Sales	-179.47%	-39.48%	-43.66%	-16.05%	-10.94%	-8.90%
Working capital/Sales	24.13%	46.88%	28.09%	18.34%	12.83%	9.99%
Cash Conversion Cycle (in days)	140	191	117	73	39	22
Trading multiples						
EV/Sales	8.13	14.59	11.66	6.01	3.90	3.01
EV/EBITDA	125.17	-27.14	-58.05	44.73	21.38	13.35
EV/EBIT	808.85	-21.18	-33.57	117.16	31.67	17.18
P/Tangible BVPS	4.34	5.64	7.05	6.99	6.09	4.81
P/E	-558.33	-20.68	-28.63	841.37	47.54	22.76
P/FCF	150.45	-16.27	-25.28	-49.36	133.40	27.11

Disclaimer

This document (prepared on November 12, 2025) constitutes neither an offer nor a solicitation to buy or sell any security. It is for information purposes only. This document merely contains a non-binding expression of opinion on the investment instruments addressed and the market conditions at the time of publication of the document. Due to its content, which serves to provide general information, this document is not a substitute for personal and property-related advice when making investment decisions and does not convey the information that is fundamental to an investment decision and that is formulated in other sources, in particular in duly authorized prospectuses. The data used in this document alone and the statements made are based on sources that we consider to be reliable. However, we do not guarantee their accuracy or completeness. Opinion statements contained herein reflect the personal judgement of the author at a specific point in time. These opinions are subject to change at any time without notice. Any liability of the analyst or the institutions commissioning him for direct or indirect damages is excluded. This confidential report is only made available to a limited circle of recipients. Forwarding or distribution to third parties is only permitted with the authorization of East Value Research GmbH.

All applicable capital market rules relating to the preparation, content and distribution of research in the various national jurisdictions must be applied and complied with by both the supplier and the recipient. Distribution in the United Kingdom: The document is for distribution only to persons who are authorized persons or exempt persons within the meaning of the Financial Services Act 1986 or any enactment made under it or to persons described in Article 11(3) of the Financial Act 1986 (Investments Advertisements) (Exemptions) Order 1996 (as amended) and is not intended to be passed on, directly or indirectly, to any other person.
Neither the document nor any copy thereof may be taken, transferred or distributed in the United States of America, Canada, Japan or any of their territories or possessions.

Notice pursuant to MiFID II:

This publication has been commissioned by Medicalgorithmics S.A.

Sources of information:

The main sources of information for the preparation of this analysis are publications by the issuer and publicly available information from domestic and foreign media that East Value Research considers to be reliable. In addition, discussions were held with members of the management or the investor relations department of the company concerned in order to prepare the analysis. All prices of financial instruments quoted in this financial analysis are closing prices on the date stated in the analysis (or the previous day), unless another date is expressly stated. This publication is updated on occasions which East Value Research believes may be price-relevant. Reference is made in advance to the discontinuation of regular commentary on events in connection with the issuer (coverage).

Key principles and benchmarks of the value judgements contained in the document:

The valuations on which East Value Research's investment judgements are based are generally recognized and widely used methods of fundamental analysis, such as the DCF model, peer group comparisons, dividend discount model and, where appropriate, a sum-of-the-parts model.

Meaning of the investment judgement:

Buy: Based on our analysis, we expect the stock to appreciate and generate a total return of at least 10% over the next twelve months

Add: Based on our analysis, we expect the stock to appreciate and generate a total return between 0%- 10% over the next twelve months

Reduce: Based on our analysis, we expect the stock to cause a negative return between 0% and -10% over the next twelve months

Sell: Based on our analysis, we expect the stock to cause a negative return exceeding -10% over the next twelve months

The respective supervisory authority is:

Bundesanstalt für Finanzdienstleistungsaufsicht
Graurheindorfer Straße 108
53117 Bonn